In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Catalyst Pharma (CPRX), with a price target of $10. The company’s shares opened today at $3.25.
“. We reiterate our Overweight rating and increase our PT to $10 from $9 on CPRX following the company’s 4Q18 earnings call this AM. Despite just 2 months into the launch, we are impressed by the initial metrics reported today for Firdapse, with faster than expected transitioning of patients on 3,4-DAP to commercial drug, favorable insurance timelines and a growing number of new patients that were not previously on 3,4-DAP. The company reported net loss of $0.14 for the quarter and $0.33 for the year, and ended 2018 with $58.5M in cash.”
According to TipRanks.com, Duncan is a 4-star analyst with an average return of 3.8% and a 50.5% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Crinetics Pharmaceuticals Inc, and KalVista Pharmaceuticals Inc.
Catalyst Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.05 and a one-year low of $1.85. Currently, Catalyst Pharma has an average volume of 1.09M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder.